Subtype
Lung Squamous Cell Carcinoma
CI-CAN-00003121LSCC · LUSCExplore in graph →
37 active trials14 evidence items
- NCIt
- C3493
- OncoTree
- LUSC
- DOID
- 3907
- UMLS CUI
- C0149782
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003121LSCC · LUSCExplore in graph →
Clinical trials
141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER |
| 1 |
| Mar 25, 2020 |
| clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01948141 | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | completed | Phase 2 | 6 | Roswell Park Cancer InstituteOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT01660399 | Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy | unknown | Phase 2 | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT02009605 | Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer | unknown | Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT01969955 | Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer | unknown | Phase 2 | 50 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 25, 2014 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours(FGFR) | unknown | Phase 2 | 48 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00387374 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 0 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 23, 2020source: clinicaltrials